Navigation Links
MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint
Date:10/20/2010

ROCKVILLE, Md. and INDIANAPOLIS, Oct. 20 /PRNewswire-FirstCall/ -- MacroGenics, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the Protege Data Monitoring Committee (DMC), composed of independent experts in the fields of diabetes and biostatistics, has completed a planned analysis of one-year safety and efficacy data of the Protege Phase 3 clinical trial of teplizumab, an investigational biologic under development for the treatment of individuals with recent-onset type 1 diabetes.

The DMC concluded that the primary efficacy endpoint of the study, a composite of a patient's total daily insulin usage and HbA1c level at 12 months, was not met. The DMC, noting that all administration of experimental drug had been completed, commented that appropriate safety monitoring is warranted. No unanticipated safety issues were identified in the DMC's review.

"We will comply with the DMC's recommendations," said Scott Koenig, M.D., Ph.D., President and Chief Executive Officer, MacroGenics. "We remain committed to discovering and developing novel biologics for the treatment of autoimmune disorders like type 1 diabetes."

Following careful evaluation of the DMC's recommendations for Protege, based on the lack of efficacy, the companies have decided to suspend further enrollment and dosing of patients in two other ongoing clinical trials of teplizumab in type 1 diabetes: the Protege Encore Trial, a second Phase 3 trial of the same design as Protege, and the SUBCUE trial, a Phase 1b trial that is exploring the subcutaneous administration in patients with type 1 diabetes.

"The failure to meet the primary endpoint is obviously disappointing for the millions of people who live with and treat type 1 diabetes," said Gwen Krivi, Vice President, Product Development, Lilly Diabetes. "Lilly and MacroGenics will be considering all options for teplizumab in type 1 di
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
3. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
4. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
5. Lilly and Glenmark Pharmaceuticals Announce License Agreement
6. Lilly Receives NCQA Design Certification for Depression Care Management Program
7. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
8. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
9. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
10. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
11. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015 /CNW/ - ChipCare Corporation, a ... blood-testing platform for HIV and other infectious and ... A financing to bring its first-generation product to ... products. (Photo: http://photos.prnewswire.com/prnh/20150303/179107 ) ... settings to simple, accurate and affordable diagnostic tests ...
(Date:3/3/2015)... Mar. 03, 2015 Research and Markets ... PharmaBiotech,s new report "Cardiovascular Drug Delivery - Technologies, ... Drug delivery to the cardiovascular system is ... anatomy and physiology of the vascular system; it supplies ... Drugs can be introduced into the vascular system for ...
(Date:3/3/2015)... DENVER , March 3, 2015  Tru-D ... at the Association for Perioperative Registered Nurses, Surgical ... Colorado , during Patient Safety Awareness Week ... with resources for safe clinical practice and professional ...   Photo - http://photos.prnewswire.com/prnh/20150302/178998LOGO   ...
Breaking Medicine Technology:ChipCare Closes Oversubscribed $5 Million Series A Financing 2ChipCare Closes Oversubscribed $5 Million Series A Financing 3Global Cardiovascular Drug Delivery Technologies, Markets and Companies 2014-2024 2Global Cardiovascular Drug Delivery Technologies, Markets and Companies 2014-2024 3Tru-D SmartUVC to Exhibit Most Effective UV Disinfection Robot at AORN Surgical Conference and Expo 2015 2Tru-D SmartUVC to Exhibit Most Effective UV Disinfection Robot at AORN Surgical Conference and Expo 2015 3
... N.J., Dec. 13, 2010 PharmaNet Development Group, ... to pharmaceutical, biotechnology, generic drug and medical device ... launching two technology platforms – Initiator™ and PKS™ ... study timelines by accelerating data acquisition and the ...
... MedShape Solutions, Inc., the world,s leading developer of ... today announced a strategic investment and development agreement ... identifies innovative technology solutions to support the missions ... MedShape,s business is built on a technology platform ...
Cached Medicine Technology:PharmaNet's Technology Investments Translate to Enhanced Client Service in Its Phase I Clinics 2PharmaNet's Technology Investments Translate to Enhanced Client Service in Its Phase I Clinics 3MedShape Solutions, Inc. Secures Investment From IQT to Support U.S. Intelligence Community 2
(Date:3/3/2015)... Aliso Viejo, California (PRWEB) March 03, 2015 ... new animated effect entitled inMotion3D Environment from Pixel Film ... turns a 2D HDRI image into 360° viewing area ... Film Studios. “inMotion3D Environment blurs the line between professional ... , Motion 5 users can turn their 2D HDRI ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Aureus Medical ... including Physician jobs, has announced that it will participate ... be held Tuesday, March 17, 2015 in St. Louis, ... opportunity to meet job-seeking residents and fellows in a ... physician division will be available to speak with ...
(Date:3/3/2015)... Aliso Viejo, California (PRWEB) March 03, 2015 ... Studios have announced the release of a new plugin ... , “FCPX3D Confetti animates an exploding transition using confetti ... Film Studios. “When adding an FCPX3D Confetti transition, users ... this FCPX Plugin.” , Transition from one clip to ...
(Date:3/2/2015)... 2015 Formetco today announced the official ... The FTX uses state-of-the-art technology to deliver an outdoor ... owner satisfaction. An item of particular value, and ... 10 year LED Brightness Warranty. , Why the FTX ... superior billboard among any other billboard product in the ...
(Date:3/2/2015)... Boston/Framingham (PRWEB) March 02, 2015 Getting ... freezer section is the goal this March as the ... was designated by the National Frozen & Refrigerated Foods ... food offers. Ian’s offers more than 20 delicious frozen ... exciting month. , The tasty frozen options are crafted ...
Breaking Medicine News(10 mins):Health News:A New Plugin Entitled inMotion3D Environment Was Released Today from Pixel Film Studios Exclusively for Motion 5 2Health News:A new Confetti Generator entitled FCPX3D Confetti was released today from Pixel Film Studios for Final Cut Pro X 2Health News:Formetco Launches Innovative LED Billboard System 2Health News:Take a Fresh Look at Frozen with Ian’s 2
... Binge drinking may not necessarily kill or even damage brain ... But it can block key receptors in the brain and ... critical to learning and memory, according to researchers. Neuroscientists ... their findings not only shed light on exactly what is ...
... Of 180 patients in this study in whom a ... had originally been misdiagnosed by their family doctors as ... colleagues present the results of their cross-sectional study in ... (Dtsch Arztebl Int 2011; 108[26]: 445-51). When a ...
... Misinformation about venomous spiders and spider bites often leads emergency ... creatures for "necrotic" skin lesions, new research indicates. Necrotic ... die due to a lack of blood and oxygen, and ... necrotic lesions on the skin are typically not the result ...
... patients and for the first time researchers have found ... heart failure outcomes, a highlight of the recent American ... was the need to establish the mechanisms by which ... Christopher S. Lee, PhD, RN of the Oregon ...
... July 13 (HealthDay News) -- Rural workers are often forced to ... and their jobs, researchers report. According to the study ... New Hampshire, people who work in rural communities have less access ... or lost jobs and caring for themselves or a family member ...
... that are designed to suppress the formation of new ... slowed cancer growth in some patients. However, they have ... might. Now, research from the Perelman School of Medicine ... the modest responses. The discovery, published in the July ...
Cached Medicine News:Health News:Rat Study Shows How Binge Drinking Harms Memory 2Health News:Skin Lesions Often Misdiagnosed as Spider Bites 2Health News:Heart failure: Doing what your doctor says works 2Health News:Rural Workers Often Lack Access to Sick Leave 2Health News:Penn study shows link between immune system suppression and blood vessel formation in tumors 2
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
Medicine Products: